Clinical Trial Update: Low-dose Pembrolizumab Plus Chemotherapy for the First-Line Treatment of Persistent, Recurrent, or Metastatic Cervical Cancer. [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating low-dose pembrolizumab in combination with chemotherapy as first-line treatment for persistent, recurrent, or metastatic cervical cance…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cervical Cancer

Drugs mentioned

• Pembrolizumab (pembrolizumab)

Snippet

Sponsor: Instituto Nacional de Cancer, Brazil | Conditions: Persistent, Recurrent, or Metastatic Cervical Cancer | Phase 2 | Status: RECRUITING